Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

New Tool in the AMR Fight: Synthetic RNA That Hugs Bad Bacterial RNA and Won’t Let Go

by Kristen Eller
August 9, 2021
New Tool in the AMR Fight: Synthetic RNA That Hugs Bad Bacterial RNA and Won’t Let Go

Colorized scanning-electron micrograph showing carbapenem-resistant Klebsiella pneumoniae interacting with a human white blood cell. Credit: NIAID, modified.

The Big Idea

A new technique my colleagues and I developed that can kill deadly, multidrug-resistant bacteria in real time could be used to generate targeted therapies that replace traditional, increasingly ineffective antibiotics.

Bacteria follow the same basic genetic process that all organisms do: DNA, which contains instructions on how an organism will look and function, is copied into an intermediate form called RNA that can be translated into proteins and other molecules the organism can use.

Diagram of PNA interrupting the basic biological process of DNA being converted to protein.
PNAs can be introduced to interrupt the process in which DNA is converted into protein or other useful biological molecules necessary for life. Kristen Eller, CC BY-ND

The technique we developed at the Chatterjee Lab at the University of Colorado Boulder uses a synthetic version of RNA called PNA, or peptide nucleic acid, to disrupt this basic process in bacteria. Our PNA molecule clings to the bacterial RNA, blocking it from carrying out its job. Because this molecule is a perfect match to bacterial RNA, it binds very tightly to the RNA and resists degradation. This means that it can not only escape the bacteria’s error detection processes but also prevent that RNA from being translated into proteins and other useful biological molecules. This impediment can be lethal to the bacteria.

Our study, which we recently published in Communications Biology, demonstrates the therapeutic potential of a technique that can design, synthesize and test PNA treatments in under a week.

Most antibiotics aren’t specific enough to target only infectious bacteria without also destroying the body’s good bacteria. Our technology, however, uses noninfectious versions of multidrug-resistant bacteria to create highly specific molecules. By targeting just the pathogen of interest, these PNA therapeutics may avoid the harm that current antibiotics pose to the body’s good bacteria.

Diagram depicting a new methodology of designing, synthesizing, testing and delivering therapies against multidrug-resistant bacteria.
The Facile Accelerated Specific Therapeutic (FAST) platform can produce therapies against multidrug-resistant bacteria in under a week. Kristen Eller, CC BY-ND

Why It Matters

Bacteria’s adaptation to survive current antibiotics, or antibiotic resistance, is on the rise.

Medicine’s current arsenal of treatments mostly consist of naturally occurring antibiotics that were isolated more than 30 years ago. Discovery of new antibiotics in nature has stagnated while bacteria continue to evolve and evade current treatments. And even if scientists were to find a new natural antibiotic, research shows that bacteria will begin to develop resistance within as little as 10 years, leaving us in the same predicament as before.

New types of therapies need to be considered for a post-antibiotic era, a time when our arsenal of antibiotics is no longer effective. By using a system that can target specific bacteria and be continuously modified based on emerging resistance patterns, doctors would no longer have to rely on chance discoveries. Treatments can adapt with bacteria.

What Still Isn’t Known

Although we explore multiple characteristics that determine which RNA sequences are the best targets, more research is necessary to identify the most effective PNA therapeutics against multidrug-resistant bacteria. As our study only tested our new strategy on cell cultures in the lab, we’ll also need to see how it works in living animals to maximize the effectiveness of this kind of treatment.

What’s Next

Our team is currently testing the technology in different animal models against different types of infections. We are also exploring other PNA delivery options, including adapting our bacterial delivery system to probiotic strains so it can integrate with the existing healthy bacteria population in the body.

With further development, our goal is to adapt the platform to target diseases that also use the same basic genetic processes as bacteria, such as viral infections or cancer.

Facile accelerated specific therapeutic (FAST) platform develops antisense therapies to counter multidrug-resistant bacteria. Communications Biology, 12 March 2021.

ABOUT THE AUTHOR

Kristen Eller, PhD Candidate in Chemical Engineering, University of Colorado Boulder. I am currently a PhD candidate in the Chemical Engineering program at the University of Colorado Boulder. I obtained my Master of Science degree in Chemical Engineering from the University of Colorado Boulder in 2018 and obtained my Bachelor of Science in Chemical-Biological Engineering from the Massachusetts Institute of Technology in 2016. I have been conducting multi-disciplinary research in developing novel antimicrobial therapies throughout the past 5 years, producing numerous publications including three coauthor publications on antimicrobial nanoparticles, a first author publication on anti-sense antimicrobials, and a co-first author publication on gene editing strategies to multi-drug resistant bacteria.

This article is courtesy of The Conversation.

Tags: Antibiotic ResistanceAntimicrobialsBiotechnologyEditor PickInnovation

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy